Cue Biopharma Enters Material Definitive Agreement
Ticker: CUE · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1645460
Sentiment: neutral
Topics: material-definitive-agreement, corporate-action
TL;DR
Cue Biopharma just signed a big deal, filing an 8-K on Oct 2nd.
AI Summary
On October 2, 2024, Cue Biopharma, Inc. entered into a material definitive agreement. The company, formerly known as Imagen Biopharma, Inc., is incorporated in Delaware and headquartered in Boston, Massachusetts.
Why It Matters
This filing indicates a significant new contract or partnership for Cue Biopharma, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement is a significant event that could carry substantial implications, both positive and negative, for the company.
Key Numbers
- 001-38327 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-3324577 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- October 2, 2024 (date) — Date of Report
- Imagen Biopharma, Inc. (company) — Former Company Name
- Boston, Massachusetts (location) — Principal Executive Offices
- 40 Guest Street (location) — Business Address
FAQ
What is the nature of the material definitive agreement Cue Biopharma, Inc. entered into?
The filing states that Cue Biopharma, Inc. entered into a material definitive agreement on October 2, 2024, but the specific details of the agreement are not provided in this excerpt.
When was the report filed with the SEC?
The report was filed as of date October 4, 2024.
What was Cue Biopharma, Inc.'s former name?
Cue Biopharma, Inc.'s former name was Imagen Biopharma, Inc., with a date of name change on June 17, 2015.
Where is Cue Biopharma, Inc. headquartered?
Cue Biopharma, Inc.'s principal executive offices are located at 40 Guest Street, Boston, Massachusetts, 02135.
What is the Standard Industrial Classification code for Cue Biopharma, Inc.?
The Standard Industrial Classification code for Cue Biopharma, Inc. is PHARMACEUTICAL PREPARATIONS [2834].
Filing Stats: 600 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-10-04 16:00:07
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market
- $20,000,000 — e Company at SVB cash equal to at least $20,000,000 (the "Threshold Amount"). The Second Am
Filing Documents
- cue-20241002.htm (8-K) — 55KB
- cue-ex10_1.htm (EX-10.1) — 44KB
- 0000950170-24-112887.txt ( ) — 240KB
- cue-20241002.xsd (EX-101.SCH) — 44KB
- cue-20241002_htm.xml (XML) — 4KB
01
Item 1.01. Entry into a Material Definitive Agreement. On October 2, 2024 (the "Effective Date"), Cue Biopharma, Inc. (the "Company") entered into a second amendment (the "Second Amendment") to its Loan and Security Agreement dated as of February 15, 2022 with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company ("SVB"), as amended by that certain Waiver and First Amendment to Loan and Security Agreement dated as of April 10, 2023. As of the Effective Date, the Second Amendment removes the requirement for the Company to maintain in accounts of the Company at SVB cash equal to at least $20,000,000 (the "Threshold Amount"). The Second Amendment retains the requirement that the Company have at all times on deposit in accounts of the Company maintained with SVB, unrestricted and unencumbered cash in an amount equal to the lesser of (i) the Threshold Amount and (ii) 100% of the dollar value of the Company's consolidated cash, in the aggregate, at all financial institutions. The foregoing summary of the Second Amendment is qualified in its entirety by reference to the full text of the Second Amendment, a copy of which is filed as Exhibit 10.1 hereto.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 10.1 Second Amendment to Loan and Security Agreement, dated October 2, 2024, by and between Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, and Cue Biopharma, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cue Biopharma, Inc. Date: October 4, 2024 By: /s/ Daniel R. Passeri Name: Daniel R. Passeri Title: Chief Executive Officer